SE
Therapeutic Areas
CG Oncology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Cretostimogene grenadenorepvec (CG0070) | BCG-unresponsive NMIBC with Carcinoma in Situ (CIS) ± Ta/T1 tumors | Phase 3 |
| Cretostimogene grenadenorepvec | BCG-naïve High-Risk NMIBC | Phase 3 |
| Cretostimogene + Pembrolizumab | BCG-unresponsive NMIBC (CIS-containing) | Phase 2 |
| Cretostimogene + Nivolumab | Muscle-Invasive Bladder Cancer (MIBC) | Phase 2 |
Leadership Team at CG Oncology
AK
Arthur Kuan
Chairman & Chief Executive Officer
AB
Ambaw Bellete
President & Chief Operating Officer
VK
Vijay Kasturi
Chief Medical Officer
SB
Swapnil Bhargava
Chief Technical Officer
JP
Josh Patterson
General Counsel & Chief Compliance Officer
BL
Brian Liu
Board Member
JM
Jim Mulé
Board Member
LP
Leonard Post
Board Member
CR
Christina Rossi
Board Member
VT
Victor Tong, Jr.
Board Member